Key Highlights
- The quarter beat on Revenue and EPS, but maintained rather than raised procedure guidance, and US da Vinci growth slowed to 12% from 14%, the deceleration, not the results, drove the 14.1% single-day fall.
- Recurring instruments and accessories revenue of $1.73 billion, up 18%, against a da Vinci installed base of 11,710 systems remains the durable part of the model.
- Competition is now real: Hugo cleared in December 2025 and Ottava authorized at last closing, alongside genuine pricing pressure in China.
- Few MedTech companies could match the raw numbers Intuitive Surgical posted on 16 July.
A beat that lost the argument
Few medtech companies could match the raw numbers Intuitive Surgical ( Nasdaq :ISRG) posted on 16 July. Second-quarter revenue rose 19% to $2.89 billion, non-GAAP Earnings reached $2.80 per diluted share, and worldwide procedures across the company's platforms grew roughly 16%. Both headline figures cleared Wall Street , which had modeled about $2.82 billion of revenue and $2.51 of adjusted EPS.
Investors sold anyway, and the reason sat in the outlook rather than the quarter. Management left 2026 da Vinci procedure growth at 13.5% to 15.5% and steered analysts toward the midpoint, roughly 14.5%, below the approximately 15.3% the sell side had penciled in after April's guidance raise. Underneath that, US da Vinci procedure growth decelerated to 12% from 14% in the first quarter. Chief executive Dave Rosa told analysts growth in the US "moderated from recent trends," concentrated "predominantly in procedures that can be deferred."
Two specific pressures were identified. Chief financial officer Jamie Samath pointed to patients affected by the expiration of enhanced Affordable Care Act premium subsidies, which appears to be pushing elective cases later. Separately, US bariatric volumes on da Vinci declined by high single digits as GLP-1 medicines continue to substitute for weight-loss surgery.
A de-rating, not a breakdown
The market's response was blunt. Shares closed at $345.42 on 17 July, down 14.1% from the previous session's $402.33, on Volume near 11.6 million shares against 5.7 million a day earlier, a 52-week low. Prices have since steadied, closing at $353.33, a gain of 0.1% on the day, for a market Capitalization of about $124.8 billion.
The twelve-month picture is what should concern holders more than one session. ISRG is down roughly 29% over a year and trades about 41% below its 52-week high of $603.88. That is a compression of one of large-cap medtech's most expensive multiples rather than evidence of a broken Business . More than a dozen firms cut price targets after the print, with Piper Sandler moving to $470 from $580 while William Blair kept an Outperform rating.
Why the installed base is the real asset
The company sells robots, but it earns its living on what runs through them. Instruments and accessories generated $1.73 billion in the quarter, up 18%, versus $685 million from systems and $472.4 million from services. That mix is the thesis: each da Vinci placed becomes an Annuity that compounds as surgeons broaden indications and hospitals add case volume.
That annuity keeps widening. The da Vinci installed base reached 11,710 systems, up 12% year over year, with 468 placed in the quarter against 395 a year earlier. Ion, the robotic bronchoscopy platform for peripheral lung biopsy, closed at 1,096 systems, up 21%. Leasing now carries much of the load, 254 of the 468 da Vinci placements, or 54%, went out under operating leases, and 52% of those were usage-based, which softens hospital capital budgets at the cost of slower revenue recognition.
The numbers behind the headline
Profitability held up better than the share reaction implied. GAAP gross Margin was 67.8% and non-GAAP 70.0%, though the latter included a $36 million pre-tax refund of tariffs collected under the International Emergency Economic Powers Act; excluding it, non-GAAP gross margin was 68.7%. GAAP Operating Income reached $972 million and non-GAAP $1.22 billion. GAAP EPS of $2.29 compared with $1.81 a year earlier. Cash and investments stood at $8.63 billion with no reported Debt , and the company bought back 0.9 million shares for $0.38 billion.
Management actually raised the full-year non-GAAP gross margin range to 68%–69% from 67.5%–68.5%, citing Tariff relief and product cost reductions, while still absorbing roughly one point of revenue in tariff cost. Non-GAAP Operating Expense growth was guided to 11%–13%, with R&D outpacing SG&A, spending ahead of a product cycle rather than defending an existing one.
Three platforms, three different clocks
Da Vinci 5 is the volume story: 246 of the quarter's placements, up from 180 a year ago. The system won FDA clearance for several cardiac procedures in January 2026 using non-force-feedback instruments, and the first Tranche of more than 100 planned software and workflow updates began measured US release in June. Samath cited force-feedback data showing bowel function recovery within one day in 63% of cases against 28% without it, clinically interesting, and commercially the argument for premium pricing.
Ion is the fastest grower, with procedures up 36% to about 48,000 and cumulative volume past 400,000, now installed in 12 countries outside the US. The single-port SP system remains small but is inflecting, with procedures up 61% and 38 systems placed; the SP stapler was used in nearly 60% of eligible US colorectal and thoracic cases, up from 40% the prior quarter.
The case for buying weakness
Bulls argue the deceleration is macro and pharmacological, not competitive. Installed base growth of 12%, instrument revenue growth of 18% and a 20% first-half revenue increase to $5.66 billion do not describe share loss. Cardiac, SP and Ion all address populations da Vinci has barely touched, and the recurring-revenue base means procedure growth flows through even when system sales are lumpy. The consensus of 33 analysts remains Buy, with an average target of $477.25.
The case for staying cautious
The bear argument is that two structural headwinds arrived at once. Rosa described China plainly: "the environment remains challenging," with "lower tender activity, increased domestic robotic competition, and policy-driven pricing pressure." and the US Monopoly has ended. Medtronic's Hugo won FDA clearance for urologic procedures in December 2025; Johnson & Johnson's Ottava received de novo authorization at last closing across ten general-surgery indications including gastric bypass, gastrectomy and cholecystectomy. J.P. Morgan expects share losses to be "very modest/immaterial" near term, but hospitals now have Leverage on price they lacked for two decades. Add GLP-1 erosion in bariatrics and tariffs, and the pricing power investors paid up for looks less absolute.
What the multiple now says
At $353.33, ISRG trades at 40.5 times trailing earnings and 31.3 times forward earnings, on 11.3 times sales and 10.8 times Enterprise value to sales, with EV/EBITDA of 28.2 and about 38.7 times free Cash Flow on $3.22 billion of trailing free cash flow. Those are still growth-stock multiples, well above the medtech average, and they embed continued mid-teens compounding. The de-rating has removed the extremes without making the shares cheap, which is why the next two procedure prints matter more than usual.
Upcoming Catalysts
- Q3 2026 results, expected mid-to-late October 2026. The decisive test of whether US procedure growth stabilizes near 12% or resumes; guidance narrowed toward the low end would confirm the bear case.
- Continued da Vinci 5 update rollout, through late 2026. Several of the 100-plus announced features require regulatory clearance before broader US deployment.
- Early Ottava and Hugo commercial placements, from H2 2026. J&J has signaled a selective launch; the first competitive displacements at named accounts will be closely tracked.
- US cardiac and SP indication expansion, ongoing. Adoption pace in cardiac, cleared January 2026, indicates whether new specialties can offset bariatric attrition.
Principal Risks
- US procedure deceleration. Deferrable-case softness tied to ACA Subsidy expiry could persist into 2027, and procedure growth is the primary valuation input.
- GLP-1 substitution. US da Vinci bariatric cases fell high single digits; if the effect spreads to other metabolic-related surgery, the addressable base shrinks.
- China. Lower tender activity, domestic robotic entrants and policy-driven pricing pressure directly threaten one of the company's largest international growth markets.
- Competitive pricing. With Hugo and Ottava cleared, hospitals gain negotiating leverage over both system pricing and instrument contracts for the first time in two decades.
- Tariffs. Guidance already absorbs roughly one point of revenue in tariff cost, and management warned additional measures beyond expectations could be material.
Conclusion
The quarter beat on revenue and EPS, but maintained rather than raised procedure guidance, and US da Vinci growth slowed to 12% from 14%, the deceleration, not the results, drove the 14.1% single-day fall. Set against that: Deferrable-case softness tied to ACA subsidy expiry could persist into 2027, and procedure growth is the primary valuation input. The next real test: The decisive test of whether US procedure growth stabilizes near 12% or resumes; guidance narrowed toward the low end would confirm the bear case.
This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...